Governance

Mixed Reality Training Takes on Opioid Overdose Crisis

Non-profit healthcare organization OSF Healthcare has partnered with Illinois State University (ISU) and Southern Illinois University Carbondale (SIU) to develop an immersive training program using Mixed Reality (MR) technology. This program aims to combat opioid overdose deaths (OD). Combining Tec…

a-female-doctor

Headline

Non-profit healthcare organization OSF Healthcare has partnered with Illinois State University (ISU) and Southern Illinois University Carbondale (SIU) to develop an immersive training program using Mixed Reality (MR) technology. This program aims to combat opioid overdose deaths…

Context

Non-profit healthcare organization OSF Healthcare has partnered with Illinois State University (ISU) and Southern Illinois University Carbondale (SIU) to develop an immersive training program using Mixed Reality (MR) technology. This program aims to combat opioid overdose deaths (OD). Combining Tech and Mannequins for Higher Accuracy

Evidence

Pending intelligence enrichment.

Analysis

Building upon the development of the Virtual Reality Embedded Naloxone Training (VENT) program, funded by the Illinois Innovation Network, this partnership focuses on integrating MR or Augmented Reality (AR) education. The goal is to train individuals in using naloxone—an antidote for suspected opioid overdoses—in an immersive and engaging manner. OSF emphasizes that the U.S. Food and Drug Administration (FDA) introduced naloxone nasal spray in March as part of its harm reduction strategy. Scott Barrows, Director of the OSF Innovation Design Lab at Jump Trading’s Simulation and Education Center, explained that the MR aspect combines the physical and virtual. The training incorporates actual spraying devices and mannequins, enabling participants to practice physical spraying while engaging in a valuable virtual environment. Barrows noted:

Key Points

Pending intelligence enrichment.

Actions

Pending intelligence enrichment.

Author

Ivy Wu (i.wu@btw.media)· author profile pending